



Lotemax® (loteprednol) – First-time generic

- On February 11, 2021, [Akorn launched](#) an [AB-rated](#) generic version of Bausch Health's [Lotemax \(loteprednol\)](#) ophthalmic gel.
- Lotemax is approved for the treatment of post-operative inflammation and pain following ocular surgery.
- Loteprednol is also available generically as an [ophthalmic suspension](#), branded ophthalmic suspensions ([Alrex®](#), [Eysuvis®](#), [Inveltys®](#)), branded ophthalmic ointment ([Lotemax](#)), branded ophthalmic gel ([Lotemax SM](#)), and a branded ophthalmic suspension in combination with tobramycin ([Zylet®](#)).
 - Loteprednol ophthalmic suspension is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
 - Alrex is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
 - Eysuvis is indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
 - Inveltys, Lotemax ointment and Lotemax SM are indicated for the treatment of post-operative inflammation and pain following ocular surgery.
 - Zylet is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
- According to IQVIA, U.S. sales of Lotemax were approximately \$35 million for the twelve months ended December 2020.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.